Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™
News Medical on MSN23h
A new treatment can adjust to Parkinson's symptoms in real timeScience X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
Medtronic is a diversified medical device maker with a global footprint. Its reliably growing dividend has helped fuel its stock performance for decades. Its shares are reasonably valued for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback